

# (12) International Application Status Report

**Received at International Bureau:** 10 September 2007 (10.09.2007)

**Information valid as of:** 20 August 2009 (20.08.2009)

**Report generated on:** 09 December 2019 (09.12.2019)

**(10) Publication number:**

WO2008/019303

**(43) Publication date:**

14 February 2008 (14.02.2008)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/US2007/075146

**(22) Filing Date:**

03 August 2007 (03.08.2007)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

11/499,844 (US)

**(31) Priority date(s):**

04 August 2006 (04.08.2006)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

11/832,893 (US)

02 August 2007 (02.08.2007)

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

**A61K 38/12** (2006.01); **C07K 5/12** (2006.01)

**(71) Applicant(s):**

ENANTA PHARMACEUTICALS, INC. [US/US]; 500 Arsenal Street Watertown, MA 02472 (US) *(for all designated states except US)*

MOORE, Joel, D. [US/US]; 64 Cliffe Avenue Lexington, MA 02420 (US) *(for US only)*

TANG, Datong [CN/US]; 35 Court Street Newton, MA 02458 (US) *(for US only)*

OR, Yat, Sun [US/US]; 169 Fayette Street Watertown, MA 02472 (US) *(for US only)*

WANG, Zhe [US/US]; 67 Westwoods Blvd. Hockessin, DE 19707 (US) *(for US only)*

**(72) Inventor(s):**

MOORE, Joel, D.; 64 Cliffe Avenue Lexington, MA 02420 (US)

TANG, Datong; 35 Court Street Newton, MA 02458 (US)

OR, Yat, Sun; 169 Fayette Street Watertown, MA 02472 (US)

WANG, Zhe; 67 Westwoods Blvd. Hockessin, DE 19707 (US)

**(74) Agent(s):**

NAKAJIMA, Suanne; Elmore Patent Law Group, P.C. 515 Groton Road, Unit 1 R Westford, MA 01886 (US)

**(54) Title (EN):** PYRIDAZINONYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

**(54) Title (FR):** INHIBITEURS DE SÉRINE PROTÉASES DE L'HÉPATITE C MACROCYCLIQUES DE TYPE PYRIDAZINONYLE

**(57) Abstract:**

**(EN):** The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

**(FR):** La présente invention concerne des composés de formule I ou leurs sels, esters ou prodrogues pharmaceutiquement acceptables, qui inhibent l'activité des sérine protéases, en particulier l'activité de la protéase NS3-NS4A du virus de l'hépatite C (VHC). En conséquence, les composés de la présente invention perturbent le cycle vital du virus de l'hépatite C et ils sont également utiles comme agents antiviraux. La présente invention concerne en outre des compositions pharmaceutiques comprenant les composés ci-dessus, destinées à être administrées à un sujet atteint d'une infection par le VHC. L'invention concerne également des procédés de traitement d'une infection par le VHC chez un sujet en lui administrant une composition pharmaceutique comprenant un composé de la présente invention.

**International search report:**

Received at International Bureau: 19 August 2008 (19.08.2008) [US]

**International Report on Patentability (IPRP) Chapter II of the PCT:**

Not available

**(81) Designated States:**

AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM